Login to Your Account

Sunovion Paying $100M Up Front

COPD Drug, Device Platform Prompts $430M Elevation Buy

By Jennifer Boggs
Managing Editor

Friday, August 31, 2012
Barely three months after reporting solid Phase IIb data for EP-101, its aerosol therapy for chronic obstructive pulmonary disease (COPD), Elevation Pharmaceuticals Inc. is being snagged in a buyout by Sunovion Pharmaceuticals Inc. in a deal valued at up to $430 million.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription